BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Avastin bevacizumab regulatory update

FDA extended the PDUFA date for a pair of sBLAs from Genentech for Avastin bevacizumab for the first-line treatment of HER2-negative metastatic breast cancer to Dec. 17 from Sept. 17. The Roche unit said it submitted additional information,...

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >